抄録
Clinical studies of Roxithromycin (RXM) in the treatment of odontogenic infections were performed, and the results were obtained as follows :
1) One hundred six patients having odontogenic infections were treated with RXM at a dose of 300 mg (150 mg × 2) per day. The clinical efficacy rate judged by the comparative score was 83.0% (“ excellent” in 19 cases and “good” in 69 cases), and that judged by the doctors was 84.0 % (“ excellent” in 20 cases and “good” in 69 cases) .
2) Side effects were observed in 4 (3.8 %) out of 106 patients and all were mild in severity.
3) Twenty strains were isolated from 11 patients.The MIC80 of RXM against gram-positive aerobes was 0.78 μg/ml, and that against anaerobes was 0.39 μg/ml. Against graim-negative aerobes, RXM had no antibacterial activity.
From the above results, RXM was judged to be a safe and useful drug in the treatment of infections in dentistry and oral surgery.
